Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.05) by 108.51 percent. This is a 120 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $6.600 million which beat the analyst consensus estimate of $2.577 million by 156.08 percent. This is a 127.59 percent increase over sales of $2.900 million the same period last year.